tiprankstipranks
Advertisement
Advertisement

Nanologica boosts purification media pipeline, buys Syntagon and launches SEK 96m equity issues

Story Highlights
  • Nanologica grew 2025 sales and narrowed losses but ended the year with low cash, while securing several new global evaluation orders for its NLAB Saga® purification media and a non-silica-based product.
  • Post year-end, the company acquired contract manufacturer Syntagon and launched directed and fully secured rights issues totaling about SEK 96 million to strengthen its finances and expand production capacity for future growth.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Nanologica boosts purification media pipeline, buys Syntagon and launches SEK 96m equity issues

Claim 55% Off TipRanks

The latest announcement is out from Nanologica AB ( (SE:NICA) ).

Nanologica reported 2025 net sales of SEK 21.1 million, up from SEK 14.5 million, while narrowing its full-year operating loss to SEK 46.8 million and loss after tax to SEK 51.3 million, though cash and cash equivalents fell sharply to SEK 3.5 million at year-end. During the fourth quarter the company secured multiple evaluation and sampling orders for its NLAB Saga® purification media from customers and distribution partners in China, the U.S., and Asia, as well as an order for a non-silica-based media linked to its broader development program.

After year-end the company acquired Södertälje-based contract manufacturer Ardena Södertälje AB, rebranded Syntagon AB, in an all-share deal designed to boost production capacity, expertise, and synergies, with expectations of positive earnings and cash flow contributions. To reinforce its strained balance sheet and fund working capital, loan set-offs, and the Syntagon purchase, Nanologica’s board approved directed share issues and a fully secured rights issue totaling approximately SEK 96 million, aiming to underpin continued growth in sales and production of NLAB Saga®.

The most recent analyst rating on (SE:NICA) stock is a Hold with a SEK0.40 price target. To see the full list of analyst forecasts on Nanologica AB stock, see the SE:NICA Stock Forecast page.

More about Nanologica AB

Nanologica AB is a Sweden-based life science company specializing in silica-based purification media for pharmaceutical manufacturing, notably its NLAB Saga® product used in biologics such as insulin. The company focuses on bioprocessing solutions for drug production and is expanding its capabilities through vertical integration in contract manufacturing and process development.

Average Trading Volume: 197,415

Technical Sentiment Signal: Sell

Current Market Cap: SEK35.87M

For detailed information about NICA stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1